A long-acting antibody to prevent HIV transmission
A Solid-Phase, Long-Acting CCR5 Monoclonal Antibody for HIV Transmission
This study is testing a new long-lasting injection of Leronlimab that could help prevent HIV transmission for up to three months, making it easier for people at risk to stay protected from the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10876469 on NIH RePORTER |
What this research studies
This research focuses on developing a new formulation of a monoclonal antibody called Leronlimab, which blocks the CCR5 receptor to prevent HIV transmission. The goal is to create a long-acting version that can be administered at home, providing protection for up to three months with just one injection. The research will involve testing the effectiveness of this antibody in animal models to determine how well it can prevent both rectal and vaginal transmission of HIV. By improving adherence to treatment, this approach aims to enhance the prevention of HIV in at-risk populations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk of HIV exposure, particularly those who may benefit from pre-exposure prophylaxis.
Not a fit: Patients who are already living with HIV or those who do not engage in behaviors that put them at risk for HIV transmission may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a highly effective and convenient method for preventing HIV transmission, significantly impacting public health.
How similar studies have performed: Previous clinical trials have shown promising results with Leronlimab, indicating that this approach has potential based on earlier successes.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Sacha, Jonah B. — Oregon Health & Science University
- Study coordinator: Sacha, Jonah B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.